Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI) -- Ignore unavailable to you. Want to Upgrade?

To: Jeffrey L. Henken who wrote (1283)	6/16/1998 11:02:00 AM
From: Dave Dalry	Respond to of 2887

Jeff, I see that you have some inaccurate information in your profile. To keep everything honest, please update your profile... Dave P.S. Happy Birthday from Brenda and Dave

To: Jeffrey L. Henken who wrote (1283)	6/16/1998 11:03:00 AM
From: Bill Rogers	Read Replies (1) \| Respond to of 2887

Hi Jeff: Back a few hundred posts, I recall reading that JNJ was talking to ABMI about JV's etc. what has happened with those talks??? Have a good week.

To: Jeffrey L. Henken who wrote (1283)	6/16/1998 11:26:00 AM
From: Dr David Summers	Read Replies (1) \| Respond to of 2887

Here"s how AVE could capitalized on ABMI: 1 The OmniCath of course addresses a $300million AV dialysis market (however the cutter-housing should be cut down about 15thousandth of an inch to accommodate the long slope that AV hyperplasia produces just distal to the anastomosis. 2 The peripheral OmniCath is just fine mechanically speaking, but ABMI should follow up on the dialog that was opened with Endosonics to put ultrasonic visualization (Radiologist love it) at the cutting window. The same goes for angioscopy (Surgeons love it). This would produce another $200 million. Both of these enhancements have already been proven in vivo with excellent results. 3 Stents: AVE doesn't have a self-expanding stent. I would promote this diversity with a super biocompatible coating, thus another $300 million. 4 The micro-filter is an easy $100 million. More and more carotid PTA's are being done and this will continue to increase exponentially. There! You have $900 million in increase potential market.